Cargando…

Optimization of a Plasma Rich in Growth Factors Membrane for the Treatment of Inflammatory Ocular Diseases

The main purpose of the present study is to develop an immunosafe fibrin membrane obtained by plasma rich in growth factors technology (is-mPRGF) with improved mechanical properties that could be applied in patients with inflammatory ocular diseases. Blood was drawn from three healthy donors and cen...

Descripción completa

Detalles Bibliográficos
Autores principales: Anitua, Eduardo, de la Fuente, María, Merayo-Lloves, Jesús, Muruzabal, Francisco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9598884/
https://www.ncbi.nlm.nih.gov/pubmed/36290475
http://dx.doi.org/10.3390/bioengineering9100508
_version_ 1784816458586390528
author Anitua, Eduardo
de la Fuente, María
Merayo-Lloves, Jesús
Muruzabal, Francisco
author_facet Anitua, Eduardo
de la Fuente, María
Merayo-Lloves, Jesús
Muruzabal, Francisco
author_sort Anitua, Eduardo
collection PubMed
description The main purpose of the present study is to develop an immunosafe fibrin membrane obtained by plasma rich in growth factors technology (is-mPRGF) with improved mechanical properties that could be applied in patients with inflammatory ocular diseases. Blood was drawn from three healthy donors and centrifuged, and the collected PRGF was activated and distributed into two groups: (i) mPRGF: a PRGF membrane maintained at 37 °C for 30 min; (ii) IS5+30: mPRGF incubated at 37 °C for 5 min and then incubated at 56 °C for 30 min. The content of both membranes was analyzed for several growth factors such as IgE and the complement activation, as well as biological activity on different ocular surface cells. Furthermore, the physical and mechanical characterizations were also evaluated. IS5+30 completely reduced the complement activity and decreased the IgE while preserving the concentration of the main growth factors. IS5+30 induced similar biological activity regarding mPRGF on the different ocular surface cells analyzed. Furthermore, no significant differences in release kinetics or fibrin degradation were observed between both membranes. Summarizing, IS5+30 totally reduces complement activity while preserving the concentration of most growth factors and their biological activity. Furthermore, the physical and mechanical properties of the fibrin membrane are preserved after heat inactivation.
format Online
Article
Text
id pubmed-9598884
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-95988842022-10-27 Optimization of a Plasma Rich in Growth Factors Membrane for the Treatment of Inflammatory Ocular Diseases Anitua, Eduardo de la Fuente, María Merayo-Lloves, Jesús Muruzabal, Francisco Bioengineering (Basel) Article The main purpose of the present study is to develop an immunosafe fibrin membrane obtained by plasma rich in growth factors technology (is-mPRGF) with improved mechanical properties that could be applied in patients with inflammatory ocular diseases. Blood was drawn from three healthy donors and centrifuged, and the collected PRGF was activated and distributed into two groups: (i) mPRGF: a PRGF membrane maintained at 37 °C for 30 min; (ii) IS5+30: mPRGF incubated at 37 °C for 5 min and then incubated at 56 °C for 30 min. The content of both membranes was analyzed for several growth factors such as IgE and the complement activation, as well as biological activity on different ocular surface cells. Furthermore, the physical and mechanical characterizations were also evaluated. IS5+30 completely reduced the complement activity and decreased the IgE while preserving the concentration of the main growth factors. IS5+30 induced similar biological activity regarding mPRGF on the different ocular surface cells analyzed. Furthermore, no significant differences in release kinetics or fibrin degradation were observed between both membranes. Summarizing, IS5+30 totally reduces complement activity while preserving the concentration of most growth factors and their biological activity. Furthermore, the physical and mechanical properties of the fibrin membrane are preserved after heat inactivation. MDPI 2022-09-27 /pmc/articles/PMC9598884/ /pubmed/36290475 http://dx.doi.org/10.3390/bioengineering9100508 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Anitua, Eduardo
de la Fuente, María
Merayo-Lloves, Jesús
Muruzabal, Francisco
Optimization of a Plasma Rich in Growth Factors Membrane for the Treatment of Inflammatory Ocular Diseases
title Optimization of a Plasma Rich in Growth Factors Membrane for the Treatment of Inflammatory Ocular Diseases
title_full Optimization of a Plasma Rich in Growth Factors Membrane for the Treatment of Inflammatory Ocular Diseases
title_fullStr Optimization of a Plasma Rich in Growth Factors Membrane for the Treatment of Inflammatory Ocular Diseases
title_full_unstemmed Optimization of a Plasma Rich in Growth Factors Membrane for the Treatment of Inflammatory Ocular Diseases
title_short Optimization of a Plasma Rich in Growth Factors Membrane for the Treatment of Inflammatory Ocular Diseases
title_sort optimization of a plasma rich in growth factors membrane for the treatment of inflammatory ocular diseases
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9598884/
https://www.ncbi.nlm.nih.gov/pubmed/36290475
http://dx.doi.org/10.3390/bioengineering9100508
work_keys_str_mv AT anituaeduardo optimizationofaplasmarichingrowthfactorsmembraneforthetreatmentofinflammatoryoculardiseases
AT delafuentemaria optimizationofaplasmarichingrowthfactorsmembraneforthetreatmentofinflammatoryoculardiseases
AT merayollovesjesus optimizationofaplasmarichingrowthfactorsmembraneforthetreatmentofinflammatoryoculardiseases
AT muruzabalfrancisco optimizationofaplasmarichingrowthfactorsmembraneforthetreatmentofinflammatoryoculardiseases